The Liver Meeting 2019-NAFLD Debrief

Video Transcription

Video Summary

The video transcript covers a wide range of topics related to NAFLD, including diagnostic tools such as the Dallas Steatosis Index for predicting NASH cirrhosis and a stool-based microbiome signature for outcomes prediction. It also discusses management strategies like very low-calorie diets, duodenal mucosal resurfacing, and monitoring with Pro-C3 for fibrosis regression. The role of genetic risk scores in predicting fatty liver, the potential benefits of exercise-induced biomarkers like Heat Shock Cognate 70, and various pharmacotherapies for NAFLD are highlighted, with insights from studies on drugs like cotetetide, glycoglyflozin, and FXR agonists. Additionally, the importance of comorbid conditions like depression and the impact of fibrosis on cardiovascular disease risk in NAFLD patients are addressed. These insights provide valuable information for understanding and managing NAFLD effectively.

Asset Caption

Kathleen E. Corey

Keywords

NAFLD

Dallas Steatosis Index

stool-based microbiome signature

management strategies

genetic risk scores

pharmacotherapies

fibrosis regression